Inhibitory effect of silibinin on ligand binding to erbB1 and associated mitogenic signaling, growth, and DNA synthesis in advanced human prostate carcinoma cells

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Molecular Carcinogenesis

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1002/mc.1032PMID 11346885
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Silibinin up-regulates insulin-like growth factor-binding protein 3 expression and inhibits proliferation of androgen-independent prostate cancer cells.

  2000cited by this paper
• Insulin-like growth factor physiology and cancer risk.

  2000cited by this paper
• Inhibitory effect of a flavonoid antioxidant silymarin on benzoyl peroxide-induced tumor promotion, oxidative stress and inflammatory responses in SENCAR mouse skin.

  2000cited by this paper
• The ErbB signaling network: receptor heterodimerization in development and cancer

  2000cited by this paper
• Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents.

  2000cited by this paper
• Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines.

  1999cited by this paper
• Silibinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: implications for prostate cancer intervention.

  1999cited by this paper
• Epidermal growth factor receptors: critical mediators of multiple receptor pathways.

  1999cited by this paper
• Activation of mitogen-activated protein kinase associated with prostate cancer progression.

  1999cited by this paper
• A flavonoid antioxidant, silymarin, affords exceptionally high protection against tumor promotion in the SENCAR mouse skin tumorigenesis model.

  1999cited by this paper
• The phosphatidylinositol 3'-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells.

  1999cited by this paper
• Antiapoptotic signaling in LNCaP prostate cancer cells: a survival signaling pathway independent of phosphatidylinositol 3'-kinase and Akt/protein kinase B.

  1999cited by this paper
• Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: implications in cancer chemoprevention.

  1999cited by this paper
• Inhibition of human carcinoma cell growth and DNA synthesis by silibinin, an active constituent of milk thistle: comparison with silymarin.

  1999cited by this paper
• Modulation of mitogen-activated protein kinase activation and cell cycle regulators by the potent skin cancer preventive agent silymarin.

  1999cited by this paper
• A flavonoid antioxidant, silymarin, inhibits activation of erbB1 signaling and induces cyclin-dependent kinase inhibitors, G1 arrest, and anticarcinogenic effects in human prostate carcinoma DU145 cells.

  1998influential reference
• Skin cancer chemopreventive effects of a flavonoid antioxidant silymarin are mediated via impairment of receptor tyrosine kinase signaling and perturbation in cell cycle progression.

  1998cited by this paper
• A review of plants used in the treatment of liver disease: part 1.

  1998cited by this paper
• Natural antioxidants in chemoprevention.

  1998cited by this paper
• Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study

  1998cited by this paper
• Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study.

  1998cited by this paper
• Anticarcinogenic effect of a flavonoid antioxidant, silymarin, in human breast cancer cells MDA-MB 468: induction of G1 arrest through an increase in Cip1/p21 concomitant with a decrease in kinase activity of cyclin-dependent kinases and associated cyclins.

  1998cited by this paper
• Some Perspectives on Dietary Inhibition of Carcinogenesis: Studies with Curcumin and Tea

  1997cited by this paper
• Chemoprevention of prostate cancer: The prostate cancer prevention trial

  1997cited by this paper
• New rodent models for studies of chemopreventive agents

  1997cited by this paper
• Protective effects of silymarin against photocarcinogenesis in a mouse skin model.

  1997cited by this paper
• Recent advances in chemoprevention of cancer.

  1997cited by this paper
• An Overview of Chemoprevention: Current Status and Future Prospects

  1997cited by this paper
• Properties of intraepithelial neoplasia relevant to the development of cancer chemopreventive agents

  1997cited by this paper
• The Clinical Evaluation of Cancer Prevention Agents

  1997cited by this paper
• Novel cancer chemopreventive effects of a flavonoid antioxidant silymarin: inhibition of mRNA expression of an endogenous tumor promoter TNF alpha.

  1997cited by this paper
• Skin cancer chemoprevention.

  1996cited by this paper
• Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives.

  1996cited by this paper
• Prostatic intraepithelial neoplasia (PIN) and other prostatic lesions as risk factors and surrogate endpoints for cancer chemoprevention trials

  1996cited by this paper
• Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145.

  1996cited by this paper
• Selective Cleavage of the Heregulin Receptor ErbB-4 by Protein Kinase C Activation*

  1996cited by this paper
• Diet intervention for modifying cancer risk.

  1996cited by this paper
• Prostate cancer prevention: investigational approaches and opportunities.

  1996cited by this paper
• All ErbB Receptors Other Than the Epidermal Growth Factor Receptor Are Endocytosis Impaired (*)

  1996influential reference
• Chemoprevention for prostatic intraepithelial neoplasia.

  1996cited by this paper
• Tyrosine kinase inhibition: an approach to drug development.

  1995cited by this paper
• Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms.

  1995influential reference
• Tyrosine kinase inhibition: an approach to drug development.

  1995cited by this paper
• c-erbB-2 oncogene expression in prostatic intraepithelial neoplasia: mounting evidence for a precursor role.

  1994cited by this paper
• Chapter 6 – Biochemistry of Prostatic Carcinoma

  1994cited by this paper
• Expression of p160erbB-3 and p185erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma.

  1994cited by this paper
• Chemoprevention of prostate cancer.

  1994cited by this paper
• A new approach to analysis and display of local lipophilicity/hydrophilicity mapped on molecular surfaces

  1993cited by this paper
• Growth factors and their receptors as determinants in the proliferation and metastasis of human prostate cancer

  1993cited by this paper
• Cancer chemoprevention: principles and prospects.

  1993cited by this paper
• Interaction of activated EGF receptors with coated pit adaptins.

  1993cited by this paper
• Epidermal growth factor receptor monoclonal antibody inhibits constitutive receptor phosphorylation, reduces autonomous growth, and sensitizes androgen-independent prostatic carcinoma cells to tumor necrosis factor alpha.

  1992cited by this paper
• Clathrin assembly protein AP-2 induces aggregation of membrane vesicles: a possible role for AP-2 in endosome formation

  1992cited by this paper
• Endocytosis and signals for internalization.

  1991cited by this paper
• Inhibition of prostatic tumor cell proliferation by suramin: alterations in TGF alpha-mediated autocrine growth regulation and cell cycle distribution.

  1991cited by this paper
• Colonic Cl channel blockade by three classes of compounds.

  1991cited by this paper
• Protection Against Microcystin-LR-Induced Hepatotoxicity by Silymarin: Biochemistry, Histopathology, and Lethality

  1991cited by this paper
• Autonomous growth of androgen-independent human prostatic carcinoma cells: role of transforming growth factor alpha.

  1991cited by this paper
• Epidermal growth factor.

  1990cited by this paper
• Clathrin, adaptors, and sorting.

  1990cited by this paper
• Dermatologic therapies you've probably never heard of.

  1989cited by this paper
• Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver.

  1989cited by this paper
• Antioxidants and multistage carcinogenesis in mouse skin.

  1989cited by this paper
• PREVENTION OF CCL4‐INDUCED LIVER CIRRHOSIS BY SILYMARIN

  1989cited by this paper
• 3D molecular lipophilicity potential profiles: a new tool in molecular modeling

  1988cited by this paper
• Lipophilic beta-adrenoceptor antagonists stimulate low density lipoprotein receptor activity in human skin fibroblasts.

  1987cited by this paper
• Binding to and internalization by cultured cells of neocarzinostatin and enhancement of its actions by conjugation with lipophilic styrene-maleic acid copolymer.

  1987cited by this paper
• Atomic Physicochemical Parameters for Three‐Dimensional Structure‐Directed Quantitative Structure‐Activity Relationships I. Partition Coefficients as a Measure of Hydrophobicity

  1986cited by this paper
• Development and use of quantum mechanical molecular models. 76. AM1: a new general purpose quantum mechanical molecular model

  1985cited by this paper
• [Pharmacodynamics, site and mechanism of action of silymarin, the antihepatoxic principle from Silybum mar. (L) Gaertn. 1. Acute toxicology or tolerance, general and specific (liver-) pharmacology].

  1975cited by this paper
• Epidermal growth factor

  1972influential reference
• [On the chemistry of silymarin (silybin), the active principle of the fruits from Silybum marianum (L.) Gaertn. (Carduus marianus L.)].

  1968cited by this paper
• [On the pharmacology and toxicology of silymarin, an antihepatotoxic active principle from Silybum marianum (L.) Gaertn].

  1968cited by this paper

• Immunomodulatory Phytochemicals in Cancer: Mechanistic Pathways and Translational Potential

  2026cites this paper
• Modification of mesenchymal stromal cells with silibinin-loaded PLGA nanoparticles improves their therapeutic efficacy for cutaneous wound repair.

  2024cites this paper
• Targeting beta-catenin signaling for prevention of colorectal cancer - Nutraceutical, drug, and dietary options.

  2023cites this paper
• Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions

  2022cites this paper
• Total phenolic content, free radical scavenging capacity, and anti-cancer activity of silymarin

  2020cites this paper
• Pharmacotherapeutic potential of phytochemicals: Implications in cancer chemoprevention and future perspectives.

  2018cites this paper
• Repurposed Drugs and Nutraceutical Supplements as Neglected Complements to Cancer Treatment

  2018cites this paper
• Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years

  2017cites this paper
• Silymarin and Its Role in Chronic Diseases.

  2016cites this paper
• Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells

  2015cites this paper
• Silibinin exerts cancer chemopreventive efficacy via targeting prostate cancer cell and cancer-associated fibroblast interaction

  2015cites this paper
• Bioactive Natural Products against Prostate Cancer: Mechanism of Action and Autophagic/Apoptotic Molecular Pathways

  2015cites this paper
• Restoration of the anti-proliferative and anti-migratory effects of 1,25-dihydroxyvitamin D by silibinin in vitamin D-resistant colon cancer cells.

  2015cites this paper
• Dietary Polyphenols for Prostate Cancer Therapy

  2014cites this paper
• The strategies to control prostate cancer by chemoprevention approaches.

  2014cites this paper
• Daucus carota pentane-based fractions arrest the cell cycle and increase apoptosis in MDA-MB-231 breast cancer cells

  2014cites this paper
• The binding of silibinin to ERp57.

  2014cites this paper
• Attenuation of Multifocal Cell Survival Signaling by Bioactive Phytochemicals in the Prevention and Therapy of Cancer

  2013cites this paper
• Cellular, Molecular, and Biological Perspective of Polyphenols in Chemoprevention and Therapeutic Adjunct in Cancer 71

  2013cites this paper
• Molecular Mechanisms of Silibinin-Mediated Cancer Chemoprevention with Major Emphasis on Prostate Cancer

  2013cites this paper
• Cellular and molecular targets of silibinin, a natural flavonoid, in colorectal cancer prevention and therapy

  2012cites this paper
• Tumor Cells and Tumor-Associated Macrophages: Secreted Proteins as Potential Targets for Therapy

  2011cites this paper
• Inhibition of HCV 3a core gene through Silymarin and its fractions

  2011cites this paper
• Flavonoids: A versatile source of anticancer drugs

  2011cites this paper
• Targeting silibinin in the antiproliferative pathway

  2010cites this paper
• Therapeutic Discovery Combined Treatment with Silibinin and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Overcomes Drug Resistance Caused by T 790 M Mutation

  2010cites this paper
• Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer

  2010cites this paper
• Combined Treatment with Silibinin and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Overcomes Drug Resistance Caused by T790M Mutation

  2010cites this paper
• COMPLEMENTARY AND ALTERNATIVE MEDICINE, NUTRACEUTICALS, AND DIETARY SUPPLEMENTS

  2009cites this paper
• NF‐κB in liver diseases: a target for drug therapy

  2009cites this paper
• Mechanism of the antioxidant action of silybin and 2,3-dehydrosilybin flavonolignans: a joint experimental and theoretical study.

  2008cites this paper
• MEDICINAL PROPERTIES OF MILK THISTLE WITH SPECIAL REFERENCE TO SILYMARIN AN OVERVIEW

  2008cites this paper
• Flavonoids as RTK inhibitors and potential anticancer agents

  2008influential citation
• Inducible nitric oxide synthase-vascular endothelial growth factor axis: a potential target to inhibit tumor angiogenesis by dietary agents.

  2007cites this paper
• Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized Silymarin.

  2007cites this paper
• Chemopreventive Efficacy of Silymarin in Skin and Prostate Cancer

  2007cites this paper
• Flavonoid, silibinin, inhibits proliferation and promotes cell-cycle arrest of human colon cancer.

  2007cites this paper
• Silybin and silymarin--new and emerging applications in medicine.

  2007cites this paper
• BASIC-LIVER, PANCREAS, AND BILIARY TRACT Inhibition of T-Cell Inflammatory Cytokines, Hepatocyte NF-B Signaling, and HCV Infection by Standardized Silymarin

  2007cites this paper
• Silibinin synergizes with mitoxantrone to inhibit cell growth and induce apoptosis in human prostate cancer cells

  2007cites this paper
• Pharmacokinetics of Botanical Products

  2006cites this paper
• Prostate cancer chemoprevention by silibinin: Bench to bedside

  2006cites this paper
• Natural flavonoids targeting deregulated cell cycle progression in cancer cells.

  2006cites this paper
• Mechanisms of action of novel agents for prostate cancer chemoprevention.

  2006influential citation
• Anticancer potential of silymarin: from bench to bed side.

  2006cites this paper
• Milk thistle and prostate cancer: differential effects of pure flavonolignans from Silybum marianum on antiproliferative end points in human prostate carcinoma cells.

  2005cites this paper
• End Points in Human Prostate Carcinoma Cells Flavonolignans from Silybum marianum on Antiproliferative Milk Thistle and Prostate Cancer : Differential Effects of Pure

  2005cites this paper
• Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours.

  2005cites this paper
• Cooperation between antioxidants and 1,25‐dihydroxyvitamin D3 in induction of leukemia HL60 cell differentiation through the JNK/AP‐1/Egr‐1 pathway

  2005cites this paper
• Silibinin inhibits angiogenesis via Flt-1, but not KDR, receptor up-regulation.

  2005cites this paper
• Dietary Supplementation with Silymarin Inhibits 3,2′-Dimethyl-4-Aminobiphenyl–Induced Prostate Carcinogenesis in Male F344 Rats

  2005cites this paper
• Ganoderma lucidum suppresses angiogenesis through the inhibition of secretion of VEGF and TGF-beta1 from prostate cancer cells.

  2005cites this paper
• Genetic alterations in prostate cancer.

  2005cites this paper
• Prostate cancer prevention by silibinin.

  2004cites this paper
• Targeting Multiple Signaling Pathways as a Strategy for Managing Prostate Cancer: Multifocal Signal Modulation Therapy

  2004cites this paper
• Mitogen Activated Protein kinase signal transduction pathways in the prostate

  2004cites this paper
• A cancer chemopreventive agent silibinin, targets mitogenic and survival signaling in prostate cancer.

  2004cites this paper
• Signal Transduction Targets in Androgen-independent Prostate Cancer

  2004cites this paper
• Opportunities for Targeted Molecular Therapy for Prostate Cancer

  2004cites this paper
• Silibinin sensitizes human prostate carcinoma DU145 cells to cisplatin‐ and carboplatin‐induced growth inhibition and apoptotic death

  2003cites this paper
• Epidermal Growth Factor Receptor Mediates Silibinin-Induced Cytotoxicity in a Rat Glioma Cell Line

  2003cites this paper
• Assays for complexed prostate-specific antigen and other advances in the diagnosis of prostate cancer.

  2003cites this paper
• Growth Factor-Induced Cell Motility in Tumor Invasion

  2002cites this paper
• Antioxidants induce different phenotypes by a distinct modulation of signal transduction

  2002cites this paper
• Cell Cycle 1_3

  2002cites this paper
• Luteinizing hormone-releasing hormone agonist limits DU-145 prostate cancer growth by attenuating epidermal growth factor receptor signaling.

  2002cites this paper
• Silibinin inhibits constitutive and TNFalpha-induced activation of NF-kappaB and sensitizes human prostate carcinoma DU145 cells to TNFalpha-induced apoptosis.

  2002cites this paper
• Phytochemicals as Cell Cycle Modulators A Less Toxic Approach in Halting Human Cancers

  2002cites this paper
• Silibinin inhibits constitutive and TNFα-induced activation of NF-κB and sensitizes human prostate carcinoma DU145 cells to TNFα-induced apoptosis

  2002cites this paper
• “A Comprehensive Review On Milk Thistle: Phytochemistry, Pharmacokinetics, Mechanism Of Action, And Therapeutic Potentials”

  year unknowncites this paper